Vaccine doses allocated to African countries hardest hit by mpox surge
On Nov. 6, 2024, the World Health Organization announced that the Access and Allocation Mechanism (AAM) for mpox…
-
-
living microbes discovered in 2-billion-year-old rock in South Africa
On Oct. 2, 2024, a team of researchers from the University of Tokyo announced they had discovered living…
-
Novavax received full Marketing Authorization for potype COVID-19 vaccine Nuvaxovid in UK
On Oct. 18, 2023, Novavax announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the United…
-
Biotechnology | HIV | NIH | Non-Profit Research | Therapeutics | Vaccine
Clinical trial of HIV vaccine began in United States and South Africa
On Sept. 20, 2023, the National Institutes of Health announced that a trial of a preventive HIV vaccine…
-
Novavax and Serum Institute of India announced full product registration in South Africa of Novavax COVID-19 vaccine
On Sept. 13, 2022, Novavax and Serum Institute of India, the world’s largest vaccine manufacturer by volume, announced…
-
BioNTech started construction of first mRNA vaccine manufacturing facility in Africa
On Jun. 23, 2022, BioNTech announced it had reached a milestone in the establishment of scalable mRNA vaccine…
-
WHO announced first technology recipients of mRNA vaccine hub
On Feb. 18, 2022, the WHO announced the first six countries that will receive the technology needed to…
-
Novavax and Serum Institute filed for Emergency Use Authorization of Novavax’ COVID-19 vaccine in South Africa
On Jan. 10, 2022, Novavax and Serum Institute of India announced a regulatory submission to the South African…
-
Johnson & Johnson COVID-19 vaccine demonstrated 85 percent effectiveness against hospitalization in South Africa when Omicron was dominant
On Dec. 30, 2021, Johnson & Johnson announced preliminary results from the South African Phase 3b Sisonke study…
-
Twist Bioscience began shipping synthetic RNA positive controls for Omicron (B.1.1.529/BA.1) SARS-CoV-2 variant for Development of Accurate Diagnostic Tests
On Dec. 15, 2021, Twist Bioscience announced that synthetic RNA positive controls were available for the SARS-CoV-2 Omicron…
-
First confirmed case of Omicron variant detected in the United States
On Dec. 1, 2021, the California and San Francisco Departments of Public Health confirmed that a recent case…
-
WHO announced classification of Omicron (B.1.1.529): SARS-CoV-2 variant of concern
On Nov. 26, 2021, the World Health Organization announced that the Technical Advisory Group on SARS-CoV-2 Virus Evolution…
-
Study confirmed virus variants reduce protection against COVID-19
On Aug. 26, 2021, Oregon Health & Science University (OHSU) announced a laboratory study found that blood serum…
-
MPP, WHO, AFRIGEN, BIOVAC, SAMRC and Africa CDC announced LOI for tech transfer hub in South Africa
On Jul. 30, 2021, the Medicines Patent Pool and the World Health Organization, Afrigen Biologics, the Biologicals and…
-
Cocrystal’s SARS-CoV-2 3CL protease lead CDI-45205 demonstrated broad-spectrum activity against SARS-CoV-2 Delta and Gamma variants
On Jul. 29, 2021, Cocrystal Pharma announced that its SARS-CoV-2 3CL protease lead CDI-45205 and several analogs showed…
-
Pfizer and BioNTech announced collaboration with Biovac to manufacture and distribute COVID-19 vaccine doses in Africa
On Jul. 21, 2021, Pfizer and BioNTech announced the signing of a letter of intent with The Biovac…
-
Moderna provides a clinical update on neutralizing activity of COVID-19 vaccine on emerging variants
On Jun. 29, 2021, Moderna announced new results from in vitro neutralization studies of sera from individuals vaccinated…
-
First trial participants vaccinated with Oxford COVID-19 variant vaccine
On Jun. 28, 2021, the University of Oxford in partnership with AstraZeneca began vaccinations for a new phase…
-
WHO supported South African consortium to establish first COVID mRNA vaccine technology transfer hub
On Oct. 6, 2021, the World Health Organization and its COVAX partners are working with a South African…
-
Novavax initiated COVID-19 vaccine clinical trial crossover
On Apr. 5, 2021, Novavax announced the initiation of crossover arms in two ongoing clinical trials of NVX-CoV2373,…
-
Biohaven’s multimodal antibody therapy demonstrated effective neutralization of multiple strains of COVID-19
On Feb. 22, 2021, Biohaven Pharmaceutical announced that a hyperimmune globulin mimic (HGM) developed with Biohaven’s proprietary MATE…
-
Study published in NEJM demonstrated Pfizer-BioNTech COVID-19 vaccine neutralize South African variant spike mutations
On Feb. 17, 2021, BioNTech announced results from an in vitro study that provided additional data on the…
-
Rising mortality as Africa marked one year of COVID-19
On Feb. 11, 2021, the WHO announced that COVID-19 cases and deaths surged in Africa as more contagious…
-
Pfizer and BioNTech data demonstrated COVID-19 vaccine elicited antibodies that neutralize SARS-CoV-2 mutations
On Feb. 8, 2021, Pfizer and BioNTech announced publication in Nature Medicine of data from in vitro studies…
-
ChAdOx1 nCov-19 provided minimal protection against mild-moderate COVID-19 infection from B1351 coronavirus variant in young South African adults
On Feb. 7, 2021, Oxford University announced that an analysis, submitted as a pre-print prior to peer-review publication,…
-
Corvus Pharmaceuticals initiated phase 3 clinical trial of CPI-006 for patients with COVID-19
On Feb. 4, 2021, Corvus Pharmaceuticals announced that it had initiated a Phase 3 clinical trial of CPI-006…
-
Novavax and Government of Switzerland announced agreement in principle to supply COVID-19 vaccine
On Feb. 3, 2021, Novavax announced that the company had executed a binding Heads of Terms agreement with…
-
Biotechnology | COVID-19 | WHO
New COVID-19 variants fueling Africa’s second wave
On Jan. 28, 2021, The WHO announced that COVID-19 cases and deaths were surging in Africa as more…
-
South Carolina detected first US cases associated with variant first detected in South Africa
On Jan. 28, 2021, the CDC announced that it had become aware of the first U.S. documented cases…
-
Novavax COVID-19 vaccine demonstrated 89.3% efficacy in UK phase 3 trial
On Jan. 28, 2021, Novavax announced that NVX-CoV2373, its protein-based COVID-19 vaccine candidate, had met the primary endpoint,…
